Limitations of Alzheimer’s Disease Medications

A. Pathan
{"title":"Limitations of Alzheimer’s Disease Medications","authors":"A. Pathan","doi":"10.37881/1.832","DOIUrl":null,"url":null,"abstract":"Alzheimer’s disease is an irreversible, progressive brain disorder affecting more than 6.5 million Americans that slowly destroys memory and thinking skills and, eventually, the ability to carry out simple tasks. While the specific causes of Alzheimer’s are not fully known, it is characterized by changes in the brain-including amyloid beta plaques and neurofibrillary, or tau tangles that result in the loss of neurons and their connections. These changes affect a person’s ability to remember and think. Individual responses to Alzheimer’s medications can vary. Some people may experience significant cognitive benefits, while others may have a more modest response or no response at all. The cognitive benefits provided by some medications are generally temporary. The medication may slow down the rate of cognitive decline, but it does not stop the progression of Alzheimer's disease. Some medications are more effective in the early and moderate stages of Alzheimer's disease. This article in brief described the limitations of the drugs that are used in the treatment of Alzheimer’s disease.","PeriodicalId":383954,"journal":{"name":"NeuroPharmac Journal","volume":" 42","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-12-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"NeuroPharmac Journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.37881/1.832","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Alzheimer’s disease is an irreversible, progressive brain disorder affecting more than 6.5 million Americans that slowly destroys memory and thinking skills and, eventually, the ability to carry out simple tasks. While the specific causes of Alzheimer’s are not fully known, it is characterized by changes in the brain-including amyloid beta plaques and neurofibrillary, or tau tangles that result in the loss of neurons and their connections. These changes affect a person’s ability to remember and think. Individual responses to Alzheimer’s medications can vary. Some people may experience significant cognitive benefits, while others may have a more modest response or no response at all. The cognitive benefits provided by some medications are generally temporary. The medication may slow down the rate of cognitive decline, but it does not stop the progression of Alzheimer's disease. Some medications are more effective in the early and moderate stages of Alzheimer's disease. This article in brief described the limitations of the drugs that are used in the treatment of Alzheimer’s disease.
阿尔茨海默病药物的局限性
阿尔茨海默氏症是一种不可逆的渐进性脑部疾病,影响着 650 多万美国人,它会缓慢地破坏记忆和思维能力,最终丧失完成简单任务的能力。虽然阿尔茨海默氏症的具体病因尚不完全清楚,但其特征是大脑发生变化,包括淀粉样 beta 斑块和神经纤维或 tau 结,导致神经元及其连接丧失。这些变化会影响患者的记忆和思维能力。每个人对阿尔茨海默氏症药物的反应各不相同。有些人可能会在认知方面获得明显的益处,而有些人可能反应较小或根本没有反应。某些药物对认知的益处通常是暂时的。药物可能会减缓认知能力下降的速度,但并不能阻止阿尔茨海默病的发展。有些药物在阿尔茨海默病的早期和中度阶段更为有效。本文简要介绍了用于治疗阿尔茨海默病的药物的局限性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信